Molecular classification of psoriasis diseaseassociated genes through pharmacogenomic expression profiling

Pharmacogenomics Journal

Volumn 1, Issue 4, 2001, Pages 272-287

  Oestreicher, J L ^a   Walters, I B ^b   Kikuchi, T ^b   Gilleaudeau, P ^b   Surette, J ^a   Schwertschlag, U ^a   Dorner, A J ^a   Krueger, J G ^b   Trepicchio, W L ^a  

^a PFIZER INC   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Cyclosporin a; Gene expression profiling; Inflammation; Microarrays; Psoriasis; Recombinant human interleukin 11 (rhll 11)

Indexed keywords

CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 11; MESSENGER RNA; RECOMBINANT INTERLEUKIN 11; RECOMBINANT PROTEIN;

ADULT; ARTICLE; BIOSYNTHESIS; CLASSIFICATION; COMPARATIVE STUDY; DNA MICROARRAY; FEMALE; GENE EXPRESSION PROFILING; GENETICS; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; PHARMACOGENETICS; PSORIASIS; STATISTICS;

ADULT; CYCLOSPORINE; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-11; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHARMACOGENETICS; PSORIASIS; RECOMBINANT PROTEINS; RNA, MESSENGER;

EID: 0035756813     PISSN: 1470269X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500067     Document Type: Article

References (5)

1. Greaves MW, Weinstein CD. Treatment of psoriasis. NEJ Med 1995; 332; 581-588.
2. Gottlieb AB et al. Studies of the effect of cyclosporine in psoriasis in vivo: combined effects on activated T lymphocytes and epidermal regenerative maturation. J Invest Dermatol 1992; 98: 302-309.
3. 389IL-2) suggests a primary immune but not keratinocyte pathogenic basis. Nature Med 1995; 1: 442-447.
4. Bachelez H et al. Treatment of recalcitrant plaque psoriasis with a humanized non-depleting antibody to CD4. J Autoimmun 1998; 11: 53-62.
5. Trepicchio WL et al. lnterleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions. I Clin Invest 1999; 104: 1527-1537.